Noro-Moseley Partners

NMP cultivates distribution relationships with a curated group of health-plan and health-system investors that collectively cover 45 million lives, giving portfolio companies direct access to enterprise healthcare purchasers. The firm also draws on its 40-year network and the domain expertise of its operating advisor group to identify businesses with proven unit economics before they pursue institutional capital.

NMP targets early-growth companies with 50% or higher year-over-year revenue growth, revenue run rates between $2 million and $20 million, and less than $20 million in prior funding. The firm writes initial equity checks of $5 million to $20 million, typically leading or co-leading rounds.

NMP takes an active board role focused on CEO support, executive team recruitment, sales and marketing instrumentation, and exit-process management. The firm provides operating advisors who are former entrepreneurs and executives, and it has guided multiple companies through transitions from services to SaaS models before exit.

NMP invests exclusively in US-headquartered companies, with active portfolio operations in Texas, New York, Ohio, Michigan, Minnesota, Florida, Georgia, Idaho, and North Carolina. The firm describes its geographic focus as emerging technology and healthcare hubs across the United States.

The current NMP team has generated exits representing over $5 billion in aggregate enterprise value since 2015 (per firm website). Notable realized exits include Red Canary (acquired by Zscaler), Contessa (acquired by Amedisys), SupplyPike (acquired by SPS Commerce), Clearleap (acquired by IBM), and Trendkite (acquired by Cision).

NMP's public team page describes the group as having over 70 years of collective investment experience, but the firm does not name individual managing partners, general partners, or an investment committee on its website. Investment decisions appear to be made collaboratively by the core investment team based in Atlanta.

NMP restricts its mandate to B2B technology and healthcare companies, including enterprise software, AI-enabled platforms, healthcare IT, and tech-enabled services. The firm has no disclosed interest in consumer-facing businesses, hardware, deep tech outside of AI/ML, or capital-intensive sectors like manufacturing.